

30/06/2026

Dear Colleague,

RE: Prescribing of Espranor® oral lyophilisates in Turning Point Services

This is to inform you that generic buprenorphine sublingual tablets are back on the Turning Point Formulary as first line for buprenorphine. As a result, you will start to see a shift in favour of prescriptions for generic buprenorphine rather than Espranor® lyophilisates. Please ensure you maintain an adequate supply of the generic product to meet your patient needs.

We would like to remind you that Espranor® lyophilisates and generic buprenorphine sublingual tablets are not interchangeable due to differing bioavailability.

When counselling patients, please be mindful of the differing administration methods also; where Espranor® is designed to dissolve ON TOP of the tongue, generic buprenorphine tablets must be administered sublingually (UNDER the tongue).

Please be assured that Turning Point clinicians will directly consult with clients that may be switching from Espranor® to sublingual buprenorphine.

If you have any questions, clinical queries, or concerns regarding this formulary change, please do not hesitate to contact our national medicines optimisation team at medicinesoptimisation@turning-point.co.uk

Kind regards,

Mandeep Ruprai (Senior Operations Manager – Leicester City)

Jo Hall (Senior Operations Manager – Leicestershire and Rutland)

